Jaehyeon Hwang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Jaehyeon Hwang has a total of 120 co-authors. Here are the top co-authors by number of shared publications:
- Dae-Hyuk Kweon
Department of Integrative Biotechnology, College of Biotechnology and Bioengineering, Sungkyunkwan University, Seoburo 2066, Suwon, Gyeonggi 16419, Republic of Korea
5 shared publications Chiara Zurla
Wallace H. Coulter Department of Biomedical Engineering Georgia Institute of Technology and Emory University Atlanta Georgia USA
3 shared publicationsDae-Hyuk Kweon
Department of Integrative Biotechnology, College of Biotechnology and Bioengineering, Sungkyunkwan University, Suwon, 16419, Republic of Korea
3 shared publicationsHannah E. Peck
Wallace H. Coulter Department of Biomedical Engineering Georgia Institute of Technology and Emory University Atlanta Georgia USA
3 shared publications- Jae Youl Cho
Department of Integrative Biotechnology, Sungkyunkwan University, Suwon 16419, Republic of Korea
3 shared publications - Philip J. Santangelo
Wallace H. Coulter Department of Biomedical Engineering Georgia Institute of Technology and Emory University Atlanta Georgia USA
3 shared publications
Latest Publications
- Open Access
- 10 November 2026
- Published by Wiley in Advanced Materials
An Engineered Thio‐Amino Polymer Achieves Potent, Safe, and Broad Cell Type Delivery in the Lung Mapped by Spatial Transcriptomics
Efficient delivery of nucleic acids to the lung has the potential to impact future respiratory treatments. Current formulations exhibit significant limitations, including insufficient potency, single‐cell delivery characterizations, efficacy demonstrations in disease models, and toxicology assessments. Here we describe polymer 81 (P81), which, when used with hypotonic solvents, is 34.1‐ to 77.8‐fold more potent than previous polymers with various cargos for lung transfection by nebulized mRNA. Through the exploration of multiple routes of administration, P81 demonstrated a wide of range of cell‐type delivery, including bronchial airway epithelial cells, tracheal basal stem cells, and 54% of all cells in the distal lung, assessed via single‐cell spatial transcriptomics. Robust expression of mRNA‐encoded antibodies in the lung by P81 enabled quantification of target protein and successful suppression of SARS‐CoV‐2 infection. The toxicology assessments of multiple doses of P81 polyplexes via nebulization in rodents were unremarkable. Overall, P81 represents a step forward for inhaled nucleic acid delivery to the respiratory tract, positioning itself as an efficient, safe, and translatable delivery formulation.
- 10 November 2026
- Published by Wiley in Advanced Materials
Open AccessAn Engineered Thio‐Amino Polymer Achieves Potent, Safe, and Broad Cell Type Delivery in the Lung Mapped by Spatial Transcriptomics
Efficient delivery of nucleic acids to the lung has the potential to impact future respiratory treatments. Current formulations exhibit significant limitations, including insufficient potency, single‐cell delivery characterizations, efficacy demonstrations in disease models, and toxicology assessments. Here we describe polymer 81 (P81), which, when used with hypotonic solvents, is 34.1‐ to 77.8‐fold more potent than previous polymers with various cargos for lung transfection by nebulized mRNA. Through the exploration of multiple routes of administration, P81 demonstrated a wide of range of cell‐type delivery, including bronchial airway epithelial cells, tracheal basal stem cells, and 54% of all cells in the distal lung, assessed via single‐cell spatial transcriptomics. Robust expression of mRNA‐encoded antibodies in the lung by P81 enabled quantification of target protein and successful suppression of SARS‐CoV‐2 infection. The toxicology assessments of multiple doses of P81 polyplexes via nebulization in rodents were unremarkable. Overall, P81 represents a step forward for inhaled nucleic acid delivery to the respiratory tract, positioning itself as an efficient, safe, and translatable delivery formulation.
- 17 August 2026
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 703
Inhaled dry powders of mRNA polyplexes prepared by thin-film freeze-drying
- 17 August 2026
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 703
Inhaled dry powders of mRNA polyplexes prepared by thin-film freeze-drying
- 17 March 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (12) , 9925-9939
Dual-Targeting mRNA Cancer Vaccines for Simultaneous Antigen Presentation in Dendritic and Tumor Cells
Numerous clinical trials have evaluated mRNA-based cancer vaccines owing to their safety and scalability. Most approaches use lipid nanoparticles (LNPs) to deliver antigen-encoding mRNA to dendritic cells (DCs), thereby promoting antigen-specific T cell responses. However, tumors exhibit high genetic variability, which leads to heterogeneous antigen expression. Consequently, vaccines that target only DCs with specific neoantigens may not cover all tumor cell clones, allowing some to escape immune detection. To overcome these challenges, we proposed a strategy that utilizes dual-targeted LNPs designed to simultaneously enhance antigen presentation in both DCs and tumor cells. For precise targeting, the LNPs were functionalized with DEC-205-targeting antibodies (dLNPs), which specifically bind to the DEC-205 receptor, a protein highly expressed in DCs and various tumor types. To simplify the antibody functionalization step, we fused the Fc domain of the DEC-205 antibody with apolipoprotein A1 (ApoA1), which binds naturally to lipids. Following intravenous administration, dLNPs selectively accumulated in lymph nodes and tumors. Co-delivery of antigen-encoding mRNA and toll-like receptor (TLR) agonists significantly enhanced antigen presentation in both cell types, leading to robust CD8+ T cell responses. This dual-targeting strategy elicited potent antitumor effects without systemic toxicity, demonstrating its potential in overcoming immune escape and improving mRNA vaccine efficacy.
- 17 March 2026
- Published by American Chemical Society (ACS) in ACS Nano
- Vol. 20 (12) , 9925-9939
Dual-Targeting mRNA Cancer Vaccines for Simultaneous Antigen Presentation in Dendritic and Tumor Cells
Numerous clinical trials have evaluated mRNA-based cancer vaccines owing to their safety and scalability. Most approaches use lipid nanoparticles (LNPs) to deliver antigen-encoding mRNA to dendritic cells (DCs), thereby promoting antigen-specific T cell responses. However, tumors exhibit high genetic variability, which leads to heterogeneous antigen expression. Consequently, vaccines that target only DCs with specific neoantigens may not cover all tumor cell clones, allowing some to escape immune detection. To overcome these challenges, we proposed a strategy that utilizes dual-targeted LNPs designed to simultaneously enhance antigen presentation in both DCs and tumor cells. For precise targeting, the LNPs were functionalized with DEC-205-targeting antibodies (dLNPs), which specifically bind to the DEC-205 receptor, a protein highly expressed in DCs and various tumor types. To simplify the antibody functionalization step, we fused the Fc domain of the DEC-205 antibody with apolipoprotein A1 (ApoA1), which binds naturally to lipids. Following intravenous administration, dLNPs selectively accumulated in lymph nodes and tumors. Co-delivery of antigen-encoding mRNA and toll-like receptor (TLR) agonists significantly enhanced antigen presentation in both cell types, leading to robust CD8+ T cell responses. This dual-targeting strategy elicited potent antitumor effects without systemic toxicity, demonstrating its potential in overcoming immune escape and improving mRNA vaccine efficacy.
- Open Access
- 25 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 10463
Intravaginal delivery of mRNA-encoded antibodies with enhanced breadth and potency for SHIV/HIV protection
Broadly neutralizing antibodies (bnAbs) prevent HIV infection but face administration and cost challenges. We present single-chain mRNA-encoded bnAbs that improve heavy-light chain assembly and enable three enhancement approaches: co-expression, isotype selection, and engineered nanobodies. We observe enhanced in vitro neutralization through co-expression of PGT121 and VRC07 (targeting V3-glycan and CD4-binding site, respectively) and by replacing IgG constant heavy chain (IgG-CH) with IgA-CH or incorporating an IgM tailpiece into IgG-CH. While IgG versions fail to neutralize several SHIV/HIV strains, co-expressing PGT121 and VRC07 as IgM-like multimers restores neutralizing capability (IC50 < 100 ng/mL) and substantially improves breadth. Vaginal explants from rhesus macaques, treated with intravaginal aerosolized mRNAs, show robust protection against ex vivo challenges with multiple SHIV strains when PGT121 and VRC07 are co-expressed as IgM-like multimers. Our data present novel drug compositions for intravaginal mRNA delivery to prevent HIV acquisition and advance antibody-design strategies that enhance breadth and potency of existing bnAbs.
- 25 November 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 10463
Open AccessIntravaginal delivery of mRNA-encoded antibodies with enhanced breadth and potency for SHIV/HIV protection
Broadly neutralizing antibodies (bnAbs) prevent HIV infection but face administration and cost challenges. We present single-chain mRNA-encoded bnAbs that improve heavy-light chain assembly and enable three enhancement approaches: co-expression, isotype selection, and engineered nanobodies. We observe enhanced in vitro neutralization through co-expression of PGT121 and VRC07 (targeting V3-glycan and CD4-binding site, respectively) and by replacing IgG constant heavy chain (IgG-CH) with IgA-CH or incorporating an IgM tailpiece into IgG-CH. While IgG versions fail to neutralize several SHIV/HIV strains, co-expressing PGT121 and VRC07 as IgM-like multimers restores neutralizing capability (IC50 < 100 ng/mL) and substantially improves breadth. Vaginal explants from rhesus macaques, treated with intravaginal aerosolized mRNAs, show robust protection against ex vivo challenges with multiple SHIV strains when PGT121 and VRC07 are co-expressed as IgM-like multimers. Our data present novel drug compositions for intravaginal mRNA delivery to prevent HIV acquisition and advance antibody-design strategies that enhance breadth and potency of existing bnAbs.
- Open Access
- 5 June 2025
- Published by Elsevier in Journal of Ginseng Research
- Vol. 49 (6) , 671-682
Korean red ginseng mitigates pulmonary injury and enhances antiviral immunity in a low-dose pseudo-type SARS-CoV-2 infection model
- 5 June 2025
- Published by Elsevier in Journal of Ginseng Research
- Vol. 49 (6) , 671-682
Open AccessKorean red ginseng mitigates pulmonary injury and enhances antiviral immunity in a low-dose pseudo-type SARS-CoV-2 infection model
- Open Access
- 30 January 2025
- Published by Royal Society of Chemistry (RSC) in Nanoscale Advances
- Vol. 7 (7) , 2032-2038
Graphene quantum dots as potential broad-spectrum antiviral agents
Graphene quantum dots (GQDs) are proposed as potential broad-spectrum antiviral agents as their amphiphilic properties could destroy viral membranes, regardless of the type of viruses, including SARS-CoV-2 and influenza virus.
- 30 January 2025
- Published by Royal Society of Chemistry (RSC) in Nanoscale Advances
- Vol. 7 (7) , 2032-2038
Open AccessGraphene quantum dots as potential broad-spectrum antiviral agents
Graphene quantum dots (GQDs) are proposed as potential broad-spectrum antiviral agents as their amphiphilic properties could destroy viral membranes, regardless of the type of viruses, including SARS-CoV-2 and influenza virus.
- Open Access
- 23 November 2024
- Published by Elsevier in Journal of Ginseng Research
- Vol. 49 (2) , 166-178
Korean Red Ginseng relieves the inflammation and oxidative stress induced by pseudo-typed SARS-CoV-2
- 23 November 2024
- Published by Elsevier in Journal of Ginseng Research
- Vol. 49 (2) , 166-178
Open AccessKorean Red Ginseng relieves the inflammation and oxidative stress induced by pseudo-typed SARS-CoV-2
- 6 August 2024
- Published by Elsevier in Biomaterials
- Vol. 312, 122736
Preventive and therapeutic effects of a super-multivalent sialylated filamentous bacteriophage against the influenza virus
- 6 August 2024
- Published by Elsevier in Biomaterials
- Vol. 312, 122736
Preventive and therapeutic effects of a super-multivalent sialylated filamentous bacteriophage against the influenza virus
- 24 May 2024
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 64 (2) , 107216
Delivery of endolysin across outer membrane of Gram-negative bacteria using translocation domain of botulinum neurotoxin
- 24 May 2024
- Published by Elsevier in International Journal of Antimicrobial Agents
- Vol. 64 (2) , 107216
Delivery of endolysin across outer membrane of Gram-negative bacteria using translocation domain of botulinum neurotoxin
- Open Access
- 15 July 2022
- Published by Elsevier in Journal of Ginseng Research
- Vol. 47 (1) , 123-132
Production and characterization of lentivirus vector-based SARS-CoV-2 pseudoviruses with dual reporters: Evaluation of anti-SARS-CoV-2 viral effect of Korean Red Ginseng
- 15 July 2022
- Published by Elsevier in Journal of Ginseng Research
- Vol. 47 (1) , 123-132
Open AccessProduction and characterization of lentivirus vector-based SARS-CoV-2 pseudoviruses with dual reporters: Evaluation of anti-SARS-CoV-2 viral effect of Korean Red Ginseng